Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ASP2215

Known as: ASP-2215 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) remains as one of the most frequently mutated genes in acute… Expand
  • table 1
  • figure 1
Is this relevant?
Review
2018
Review
2018
Acute myeloid leukemia (AML) is a heterogeneous disease with cure rates of only 30-40% in patients <60 years old. Cytogenetic and… Expand
Is this relevant?
2016
2016
Background FMS-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in acute myeloid leukemia (AML… Expand
Is this relevant?
2016
2016
For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the… Expand
  • figure 1
  • table 1
Is this relevant?
Review
2016
Review
2016
FLT3 (Fms-like tyrosine kinase 3) inhibitors are tyrosine kinase inhibitors. The first-generation FLT3 inhibitors were developed… Expand
Is this relevant?
2015
2015
7003 Background: FLT3 Internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations are seen in 30% of AML… Expand
Is this relevant?
2015
2015
Introduction: ASP2215, a new tyrosine kinase inhibitor with activity against FMS-like receptor tyrosine kinase-3 (FLT3) and AXL… Expand
Is this relevant?
2015
2015
Introduction: ASP2215 is a highly selective inhibitor of AXL and FMS-like tyrosine kinase-3 (FLT3) receptors. ASP2215 is active… Expand
Is this relevant?
2014
2014
7071 Background: Patients with AML harboring internal tandem duplication (ITD) of FLT3 have a poor prognosis following the… Expand
Is this relevant?
2014
2014
7070 Background: Activating mutations in FLT3 receptor tyrosine kinase, characterized by internal tandem duplication (ITD) and… Expand
Is this relevant?